Alpha-1-antitrypsin (AAT) anomalies are associated with lung disease due to rapidly growing mycobacteria and AAT inhibits Mycobacterium abscessus infection of macrophages

References

• Brown-Elliot BA, Wallace RJ. Clinical and taxonomic status of pathogenic non-pigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev 2002; 15: 716–46
   PubMed Web of Science ®Google Scholar
• Field SK, Cowie RL. Lung disease due to the more common non-tuberculous mycobacteria. Chest 2006; 129: 1653–72
   PubMed Web of Science ®Google Scholar
• Marras TK, Daley CL. Epidemiology of human pulmonary infection with non-tuberculous mycobacteria. Clin Chest Med 2002; 23: 553–67
   PubMed Web of Science ®Google Scholar
• Board of Directors medical section of the American Lung Association. Diagnosis and treatment of disease caused by non-tuberculous mycobacteria. Am J Respir Crit Care Med 1997;156:S1–S25.
   PubMed Web of Science ®Google Scholar
• Falkinham JD. Epidemiology of infection by non-tuberculous mycobacteria. Clin Microbiol Rev 1996; 9: 177–215
   PubMed Web of Science ®Google Scholar
• Blank CA, Brantly M. Clinical features and molecular characteristics of a1-antitrypsin deficiency. Annals Allergy 1994; 72: 105–21
   PubMedGoogle Scholar
• Dahl M, Hersh CP, Ly NP, Berkey CS, Silverman EK, Nordestgaard BG. The protease inhibitor Pi*S allele in COPD: a meta-analyis. Eur Respir J 2005; 26: 67–76
   PubMed Web of Science ®Google Scholar
• de Serres FJ. Worldwide racial and ethnic distribution of a1-antitrypsin deficiency: summary of an analysis of published genetic epidemiological surveys. Chest 2002; 122: 1818–29
   PubMed Web of Science ®Google Scholar
• de Serres FJ, Blanco I, Fernandez-Bustillo E. Genetic epidemiology of alpha-1 antitrypsin deficiency in North America and Australia/New Zealand: Australia, Canada, New Zealand, and the United States of America. Clin Genet 2003; 64: 382–97
   PubMed Web of Science ®Google Scholar
• Feld RD. Heterozygosity of alpha-1-antitrypsin: a health risk?. Crit Rev Clin Lab Sci 1989; 27: 461–81
   PubMed Web of Science ®Google Scholar
• Hutchison DC. The epidemiology of alpha-1-antitrypsin deficiency. Lung 1990; 168(Suppl)535–42
   PubMed Web of Science ®Google Scholar
• Dahl M, Tybjaerg-Hansen A, Lange P, Vestbo J, Nordestgaard BG. Change in lung function and morbidity from chronic obstructive pulmonary disease in a1-antitrypsin MZ heterozygotes: a longitudinal study of the general population. Ann Intern Med 2002; 136: 270–9
   PubMed Web of Science ®Google Scholar
• American Thoracic Society/European Respiratory Society Statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003;168:818–900.
   PubMed Web of Science ®Google Scholar
• Pasteur MC, Helliwell SM, Houghton SJ, Webb SC, Foweraker JE, Coulden RA, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000; 162: 1277–84
   PubMed Web of Science ®Google Scholar
• Cantin AM, Woods DE. Aerosolized prolastin suppresses bacterial proliferation in a murine model of chronic Pseudomonas aeruginosa lung infection. Am J Resp Care Crit Care Med 1999; 160: 1130–5
   PubMed Web of Science ®Google Scholar
• Janciauskiene S, Larsson S, Virtala R, Jansson L, Stevens T. Inhibition of lipopolysaccharide-mediated monocyte activation, in vitro, by alpha1-antitrypsin. Biochem Biophys Res Commun 2004; 321: 592–600
   PubMed Web of Science ®Google Scholar
• Shapiro L, Pott GB, Ralston AH. Alpha-1-antitrypsin inhibits human immunodeficiency virus type-1. FASEB J 2001; 15: 115–22
   PubMed Web of Science ®Google Scholar
• Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest 2000; 118: 1480–5
   PubMed Web of Science ®Google Scholar
• Heifets L. Mycobacterial infections caused by non-tuberculous mycobacteria. Sem Respir Crit Care Med 2004; 25: 283–95
   PubMed Web of Science ®Google Scholar
• Choi HJ, Dinarello CA, Shapiro L. Interleukin-18 inhibits human immunodeficiency virus type 1 production in peripheral blood mononuclear cells. J Infect Dis 2000; 184: 560–8
   Web of Science ®Google Scholar
• Griffith DE, Girard WM, Wallace RJ. Clinical features of pulmonary disease caused by rapidly growing mycobacteria: An analysis of 154 patients. Am Rev Respir Dis 1993; 147: 1271–8
   PubMed Web of Science ®Google Scholar
• Doucet-Populaire F, Buriánková K, Weiser J, Pernodet J-L. Natural and acquired macrolide resistance in mycobacteria. Current Drug Targets Infect Disord 2002; 2: 355–70
   PubMedGoogle Scholar